Healthy Volunteers
Conditions
Brief summary
The purpose of this study is to determine the safety of synthetic beta-arbutin, a dietary supplement that aids in the prevention and treatment of calcium oxalate kidney stones, when administered to healthy human subjects.
Detailed description
The objective and purpose of this Phase I study is to investigate the safety of synthetic beta-arbutin, administered to healthy human subjects for: i) 12 weeks, at a dose of 150 mg/day, and ii) 4 weeks, at a dose of 400mg/day. Safety will be determined by assessing adverse event rates between treatment groups and mean changes relative to baseline in serum biochemical, hematological and urinary markers.
Interventions
DIETARY_SUPPLEMENTBeta-arbutin
Beta-arbutin capsules
OTHERPlacebo
Placebo capsules containing non-medicinal ingredients
Sponsors
Canadian Glycomics Network (GlycoNet)
SP Nutraceuticals Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults, aged 18-65 years * includes non-pregnant, non-breastfeeding women on adequate birth control * acceptable effective contraceptive methods for participants with child-bearing potential include: barrier methods (condoms), total abstinence, hormonal birth control methods (oral, injectable, transdermal, or intra-vaginal), intrauterine devices, and confirmed successful vasectomy of partner; * Body Mass Index (BMI) of 18.5-35 kg/m2; * Generally healthy (absence of active clinical disease as determined by serum biochemical, hematological, and urinary parameter tests as well as detailed medical history and blood pressure measurements) as assessed by the PI/QI; * Males and females of childbearing potential willing to use appropriate effective contraception for the duration of the study; * Agrees to maintain current diet and exercise routine during the study; * Ability to provide written informed consent; and * Willing to comply with all study requirements and provide urine and blood specimens over the 12-week study period..
Exclusion criteria
* Pregnant or breastfeeding women; * History of renal dysfunction; * History of macular degeneration as assessed by the PI/QI; * History of liver disease as assessed by the PI/QI; * Type I or Type II diabetes; * Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the PI/QI History of renal dysfunction, as assessed by the PI/QI; * Cancer being actively treated with systemic therapy (i.e. chemotherapy, immune therapy); * Self-reported HIV-, Hepatitis B-, and/or C-positive diagnosis; * High alcohol intake (average of \> 2 standard drinks per day); * Heavy smokers (average of \>10 cigarettes per day); * Use of cannabinoid products within 30 days of enrollment; * Any history of major surgery (i.e. inter-abdominal, inter-thoracic, inter-cranial) within the last six months, or surgery planned during the course of the study; * Known hypersensitivity to arbutin; * Allergy to all ingredients (including non-medicinal ingredients) in investigational products and placebo product * Self-reported medical or neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation; and * Clinically significant abnormal laboratory results at screening as assessed by the PI/QI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of Adverse Events (AE) | During treatment period (Day 1 to Day 84) | Number of treatment emergent adverse events according to CTCAE v5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hematology | At screening and during treatment period (day 7, day 28, day 56, day 84) | Number of clinically relevant changes in hematology markers as assessed by: hematocrit (HCT), hemoglobin (Hb), red blood cell count (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC), differential blood count (neutrophils, lymphocytes, monocytes, eosinophils and basophils), reticulocytes absolute count, and mean platelet volume (MPV). Assessments will be performed at screening and during treatment period. |
| Biochemistry | At screening and during treatment period (day 7, day 28, day 56, day 84) | Number of clinically relevant changes in serum biochemistry. Enzymes: aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma amyl transferase. Electrolytes: magnesium, sodium, potassium, chloride, calcium. Substrates: glucose (non-fasted), bilirubin (total, direct and indirect), creatinine, albumin, urea, vitamin D. Hormones: parathyroid hormone, thyroid stimulating hormone (TSH). Coagulation tests: international normalized ratio (INR), partial thromboplastin time (PTT). Assessments will be performed at screening and during treatment period. |
| Participant compliance to treatment | During treatment period (day 7, day 28, day 56, day 84) | Adherence to study protocol and study product consumption as ascertained by capsule counts |
| Urinalysis (Microscopy) | At screening and during treatment period (day 7, day 28, day 56, day 84) | Microscopy (RBC, WBC and casts \[Hyaline, Granular and Cellular\]) by thermodilatometry (TDL) may be performed at additional urinalysis time points if clinically relevant abnormalities are detected (positive result for protein or blood in dipstick). Assessments will be performed at screening and during treatment period. |
| Urine culture | At screening and during treatment period (day 7, day 28, day 56, day 84) | Urine culture will be performed to detect microorganisms. Assessments will be performed at screening and during treatment period. |
| Urinalysis (Routine) | At screening and during treatment period (day 7, day 28, day 56, day 84) | Number of clinically relevant changes in routine dipstick urinalysis which will assess: pH, specific gravity, protein, glucose, ketones, blood, nitrite, and bilirubin. Assessments will be performed at screening and during treatment period. |
Countries
Canada
Outcome results
None listed